Photo from wikipedia
1. Liu H, Wang Z, Bao F, et al; and the Dapsone Hypersensitivity Syndrome Prevention Working Group. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with… Click to show full abstract
1. Liu H, Wang Z, Bao F, et al; and the Dapsone Hypersensitivity Syndrome Prevention Working Group. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy. JAMA Dermatol. 2019;155(6):666-672. doi:10.1001/jamadermatol.2018.5360 2. Chen XS, Li WZ, Jiang C, Ye GY. Leprosy in China: epidemiological trends between 1949 and 1998. Bull World Health Organ. 2001;79(4):306-312. 3. Lun ZR, Zhu XQ, Yang TB. Leprosy in China. Lancet Infect Dis. 2012;12(1):11. doi:10.1016/S1473-3099(11)70336-X 4. Wang N, Parimi L, Liu H, Zhang F. A review on dapsone hypersensitivity syndrome among Chinese patients with an emphasis on preventing adverse drug reactions with genetic testing. Am J Trop Med Hyg. 2017;96(5):1014-1018. 5. Rege VL, Shukla P, Mascarenhas MF. Dapsone syndrome in Goa. Indian J Lepr. 1994;66(1):59-64.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!